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Apical membrane antigen 1 (AMA1) is essential
for invasion of erythrocytes and hepatocytes by
Plasmodium parasites and is a leading malarial
vaccine candidate. Although conventional anti-
bodies to AMA1 can prevent such invasion, ex-
tensive polymorphismswithin surface-exposed
loops may limit the ability of these AMA1-
induced antibodies to protect against all para-
site genotypes. Using an AMA1-specific IgNAR
single-variable-domain antibody, weperformed
targeted mutagenesis and selection against
AMA1 from threeP. falciparum strains.Wepres-
ent cocrystal structures of two antibody-AMA1
complexes which reveal extended IgNAR CDR3
loops penetrating deep into a hydrophobic cleft
on the antigen surface and contacting residues
conserved across parasite species. Compari-
son of a series of affinity-enhancing mutations
alloweddissection of their relative contributions
to binding kinetics and correlation with inhibi-
tion of erythrocyte invasion. These findings pro-
vide insights into mechanisms of single-domain
antibody binding, and may enable design of
reagents targeting otherwise cryptic epitopes
in pathogen antigens.
INTRODUCTION
Malaria is a devastating parasitic infection that threatens
approximately 40% of the world’s population (WHO/
UNICEF, 2005). Plasmodium falciparum, the most virulent
malaria parasite infecting humans, has developed resis-
tance to many of the drugs used for prophylaxis or therapy,
and the development of a vaccine or novel therapeutic
agent would represent a major advance toward controll-
ing this devastating parasitic infection. A particularly pro-1452 Structure 15, 1452–1466, November 2007 ª2007 Elseviermising vaccine candidate and potential drug target is
apical membrane antigen 1 (AMA1) (Peterson et al., 1989).
AMA1 is a type 1 integral membrane protein which is re-
leased from the micronemes onto the merozoite surface
(Alexander et al., 2006; Healer et al., 2002; Narum and
Thomas, 1994) and is located at the moving junction
between the invadingmerozoiteanderythrocytemembrane.
Here, in complex with the rhoptry neck protein PfRON4
(Alexander et al., 2006), it plays a critical role in host cell
invasion. AMA1 appears essential for parasite viability,
and orthologs are conserved across other apicomplexan
parasites (Hehl et al., 2000; Zhou et al., 2006).
Structurally, the AMA1 ectodomain consists of three
domains (I, II, III) which when correctly folded, induce
antibodies that inhibit merozoite invasion of host erythro-
cytes (Hodder et al., 2001; Kennedy et al., 2002). Whereas
some inhibitory antibodies block proteolytic processing of
AMA1 (Dutta et al., 2005), it is likely that steric inhibition of
interaction with a ligand also mediates inhibition. Because
of the extensive polymorphisms in AMA1 within Plasmo-
dium species (Cheng and Saul, 1994; Cortes et al., 2003;
Marshall et al., 1996), inhibition of merozoite invasion by
anti-AMA1 antibodies exhibits considerable strain speci-
ficity (Hodder et al., 2001; Kennedy et al., 2002). The impor-
tance of AMA1 as a target of naturally acquired protective
immune responses is not clear, but the selection pressure
exerted by host immune responses has been responsible
for at least some of the polymorphisms in AMA1 (Polley
et al., 2003). Many of these polymorphic residues are
located on flexible loops in domain I, which are recognized
by naturally occurring antibody responses.
The recent solution of the first crystallographic struc-
tures of domains I–III of P. vivax AMA1 (Pizarro et al., 2005)
and domains I and II of P. falciparum strain 3D7 AMA1 (Bai
et al., 2005) revealed that the flexible loops surround an
extended cleft or trough which is hypothesized to be a
ligand-binding site. The base of the cleft is rich in sol-
vent-exposed hydrophobic side chains, several of which
are well conserved across diverse AMA1 proteins. For ex-
ample, residue Tyr251 rises above the surface at the center
of the cleft and is conserved in Plasmodium species andLtd All rights reserved
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(Hehl et al., 2000). Conversely, most of the loops that sur-
round the cleft are polymorphic inP. falciparumand related
species (Bai et al., 2005). These flexible and diverse loops
may facilitate evasion of otherwise protective antibody
responses and also protect a conserved site(s) critical for
AMA1 function. This concept has precedence in other
important human pathogens, such as the polymorphisms
that surround the sialic acid binding pocket of influenza
neuraminidase (Varghese et al., 1998) and the conforma-
tional masking of HIV gp120 from antibodies (Kwong
et al., 2002). Importantly, development of reagents target-
ing these two epitopes has depended, respectively, upon
(1) sophisticated structure-based drug design resulting in
the anti-influenza therapeutic Relenza (Varghese, 1999)
and (2) isolation of an unusual human antibody from an
HIV patient that recognizes gp120 through heavy-chain-
only residues (Zhou et al., 2007). Thus, if the hypothesis
that AMA1 has evolved to avoid and misdirect the human
immune response is true, then effective targeting of
cross-strain AMA1 variants may well rely on nonconven-
tional or novel designed molecules.
Fortunately, the recombinant antibody armory now in-
cludes such proteins (Holliger and Hudson, 2005). For
example, single-domain antibodies represent a distinct
subclass of immune receptors where antigen binding is
encapsulated within a single immunoglobulin domain of
between 13 and 15 kDa insize (Nuttall et al., 2000). Naturally
occurring examples are the immunoglobulin new antigen
receptors (IgNARs) from sharks (Greenberg et al., 1993)
and the VHH isotype from camels and llamas (Hamers-
Casterman et al., 1993), both of which are heavy-chain ho-
modimers with no associated light chains. Although these
isotypes have followed distinct evolutionary pathways
separated by hundreds of millions of years, they display
strikingly similar three-dimensional architectures, includ-
ing large CDR3 loop regions which provide extensive var-
iability and surface area to compensate for the absence
of light-chain hypervariable regions (Nguyen et al., 2002;
Roux et al., 1998; Streltsov et al., 2004). IgNAR variable
domains (VNARs; as distinct from VH, VL, and VHH domains)
are also extremely stable, refolding without significant loss
of function after treatment under a variety of denaturing
conditions (Liu et al., 2007).
Structural studies aimed at dissecting the precise
nature of the VNAR-antigen interaction reveal that the true
antibody paratope consists of the CDR3 and CDR1 loops
with contributions from the adjacent heavy loop 4 (Stan-
field et al., 2004; Streltsov et al., 2004). There is little input
from the CDR2 region, which is severely truncated and
wraps around the lower half of the Ig framework in a man-
ner reminiscent of I set immunoglobulins (Streltsov and
Nuttall, 2005). Cocrystallographic structures of VNAR do-
mains in complex with lysozyme show the dominant and
extended CDR3 loops accessing the lysozyme active site
cleft, an epitope not normally recognized by murine mono-
clonal antibodies, which preferentially target the hydro-
phobic faces of the antigen (Stanfield et al., 2007). This
apparent preference for cleft-like structures is supportedStructure 15, 1452–146by a growing collection of crystallographic structures for
camelid VHH-antigen pairs, although in these instances a
more diverse range of CDR3 conformations has been
observed (De Genst et al., 2006).
Single-domain antibody reagents can be readily pro-
duced as recombinant proteins in heterologous systems
such as Escherichia coli, and generated as immune reper-
toires displayed on the surface of bacteriophages (phage
display) or completely translated in vitro (ribosome dis-
play). We and others have used this approach to generate
shark molecular libraries based on both type 1 and type 2
VNARs, which are distinguished by their patterns of loop-
stabilizing disulfide bond linkages (type 1, CDR3-frame-
work; type 2, CDR1–CDR3) (Dooley et al., 2003; Nuttall
et al., 2001; Simmons et al., 2007). Previously, we utilized
such libraries to isolate a low-affinity type 2 VNAR domain,
designated 12Y-2, which targeted P. falciparum strain
3D7 AMA1 with 300 nM affinity. Atypically, this VNAR
showed no interloop disulfide bonds, and mutations gen-
erated by random mutagenesis improved binding by up
to 10-fold and mapped to the laterally extended CDR3
loop region (Nuttall et al., 2004). In order to explore the
hypothesis that single-domain antibodies can target other-
wise cryptic epitopes, we have now designed molecular
libraries based on the original 12Y-2 VNAR and selected
for variants with improved binding to different AMA1s.
We report here one such family of VNARs, and describe
two VNAR-AMA1 cocrystallographic structures. Our results
allow us to better understand the mechanisms of single-
domain antibody cleft targeting and antigen recognition,
and suggest possible strategies for targeting of conserved
apicomplexan parasite epitopes.
RESULTS
A VNAR Library Targeting AMA1
The parental 12Y-2 VNAR has 300 nM affinity for P. falci-
parum AMA1 of the 3D7 strain, but does not bind strain
W2mef or HB3 AMA1s. Individual single-residue mutations
at positions Pro90 and Phe100 in the extended CDR3 loop
structure enhanced this binding affinity for AMA1 3D7 by
up to 10-fold, but did not yield broader strain specificity
(Nuttall et al., 2004). To further explore variability within
the extended CDR3 loop structure, we targeted the ten
residues at the loop tip (Leu89–Leu98 inclusive) which
dominate the proposed paratope (Figure 1A). A series of
libraries were designed which varied in length, sequence,
and coding strategies for this region. The randomization
strategy included biases toward aromatic residues tradi-
tionally overrepresented in antigen-binding loops (Collis
et al., 2003) and a bias toward hydrophobic residues at
position98 (Figure 1B). Libraryconstructionutilizeda series
of degenerative oligonucleotide primers (see Table S1 in
the Supplemental Data available with this article online)
and resulted in a final library size of >53 107 independent
clones, exhibiting extensive diversity in loop length and
amino acid sequence.
This bacteriophage-displayed library was sequentially
panned against the HB3, W2mef, HB3, and 3D7 forms of6, November 2007 ª2007 Elsevier Ltd All rights reserved 1453
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Structure of an IgNAR-P. falciparum AMA1 ComplexFigure 1. VNAR Library Design
(A) Structure of the 12Y-2 VNAR elongated CDR3. Residues Leu89–Leu98 targeted for randomization during library construction (red) form a significant
portion of the dominant CDR3 loop region (blue).
(B) Six degenerate oligonucleotide primers (KH1–KH6) were designed to yield divergent randomization patterns. Variability was introduced through
loop length variability (8–12 residues) and by incorporation of coding bias toward hydrophobic residues (blue boxes), aromatic ring structures (pink
and green boxes), or random residues (X). Libraries were cloned as cassettes into the pFab5c.His phagemid display vector.
(C) ELISA of E. coli periplasmic fractions assayed for binding to immobilized P. falciparum HB3 antigen. Clone 14I-1 shows significant binding above
background and lysozyme negative control antigen. Data are represented as the mean ± standard error of duplicate experiments.
(D) ELISA testing of affinity-purified VNAR proteins (14I-1, 14M-15, 12A-9) for cross-strain AMA1 binding. Data are represented as the mean ± standard
error of triplicate experiments.
(E) VNAR variants illustrating combinations of single affinity-enhancing mutations (black) within CDR1 and CDR3 regions (gray).1454 Structure 15, 1452–1466, November 2007 ª2007 Elsevier Ltd All rights reserved
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positive enrichment as indicated by rising phage titers
(data not shown), whereupon VNAR DNA cassettes were
rescued and subcloned into the periplasmic expression
vector pGC, and multiple E. coli periplasmic fractions
screened for binding. One particularly promising clone,
designated 14I-1, showed enhanced binding to AMA1
HB3 (Figure 1C), and testing of FLAG tag affinity-purified
protein showed significant binding to all three forms of
AMA1 but not negative control antigens (Figure 1D). DNA
sequencing revealed two mutations: (1) Phe29Leu, a previ-
ously characterized CDR1 mutant (Kopsidas et al., 2006)
derived from variability within the DNA templates used in
library construction and (2) Gly92Arg, a novel CDR3 mu-
tant. As a first step to dissecting the relative contribution
of these changes to antigen binding, a series of seven var-
iant clones incorporating combinations of previously vali-
dated affinity-enhancing mutations 14M-15 (Pro90Leu)
and 14M-8 (Phe100Leu) was produced (Figure 1E). For
consistency, position 29 was additionally back-mutated
to phenylalanine. This set of VNAR proteins was simulta-
neously expressed in E. coli and affinity purified. No signif-
icant differences were observed between the variants in
terms of purification yields or by standard protein chemis-
try techniques such as size-exclusion chromatography,
except as detailed below (Figure S1, and data not shown).
VNAR AMA1 Binding Kinetics Correlate with
Inhibition of Erythrocyte Invasion
Data on the binding kinetics of all seven VNAR proteins to
the three forms of AMA1 were obtained by Biacore bio-
sensor analysis (Table 1; Figure S2). From this compre-
hensive data set, the key findings were as follows. (1) The
parental VNARs 12Y-2, 14M-15, and 14M-8 bind AMA1
3D7 but not strains W2mef or HB3, confirming previous
findings. (2) VNAR 14I-1 showed 5 nM binding to AMA1
3D7, which is a 6-fold increase in affinity over previous var-
iants. The dominant mutation appears to be Gly92Arg, as
combination with variant Pro90Leu was not additive at the
kinetic level. (3) The mutation Phe100Leu, in combination
with Gly92Arg, produced markedly reduced binding com-
pared to the two individual variants, confirming our previ-
ous observations that modification of position 100 abro-
gates Phe29-Phe100-Tyr87 aromatic ring interactions
when combined with other CDR mutations. Such residue
combinations appear to adversely affect the VNAR tertiary
structure, resulting in lowered protein expression levels,
aberrant gel-filtration profiles, and reduced binding (Kop-
sidas et al., 2006) (data not shown). (4) Mutation Gly92Arg
results in moderate binding to AMA1 W2mef (140 nM)
and low-affinity binding to AMA1 HB3 (700 nM). (5) There
are significant kinetic differences between the interactions
of 14I1-Y2 with W2mef and HB3, and 14I1-M15 with
W2mef and HB3, suggesting, notwithstanding point 2
above, that mutation Pro90Leu contributes to enhanced
cross-strain binding even in the presence of the mutation
Gly92Arg.
Dissection of the relative contributions to binding of
the association (KA) and dissociation (KD) rates suggestsStructure 15, 1452–146that the differences in binding affinities are mostly attribut-
able to slower dissociation rates (Table 1). For example,
the dissociation constants are notably different (12Y-2
VNAR dissociates fastest, 5 times faster than the 14M-8
and 14M-15 VNARs and 20–30 times faster than 14I-1 for
AMA1 3D7). In contrast, the association rates of VNARs
14M-8, 14M-15, 14I-1, 14I1-Y2, and 14I1-M15 fall within
a narrow range of 8.32 3 104 to 1.27 3 105. However,
because of overlapping standard errors for the triplicate
set of experiments with 14I-1 and 14I1-M15, we are unable
to definitively state whether there is a significant difference
in the association rate for these two proteins.
The ability of anti-AMA1 reagents to inhibit P. falciparum
invasion of erythrocytes in in vitro culture is an important
measure of functionality and a means of identifying critical
epitopes (Basco et al., 1995; Coley et al., 2006). Thus,
a series of growth inhibition assays were performed for
the panel of recombinant VNARs against parasite strains
3D7, W2mef, and HB3, mirroring the Biacore kinetic stud-
ies (Figures 2A and 2B, and data not shown). The VNARs
14M-15, 14M-8, 14I-1, 14I1-Y2, and 14I1-M15 potently
inhibited invasion of 3D7 parasites; in contrast, minimal
inhibition was observed for 12Y-2, 14I1-M8, and the non-
binding VNAR 12A-9 (Table 2). VNARs 14I-1 and 14I1-M15
successfully inhibited AMA1 W2mef at high protein con-
centrations, but no inhibition of HB3 parasites was ob-
served (Table 2, and data not shown). Slight variations
were observed for the relative inhibitory (IC50) values be-
tween different series of experiments, consistent with
the variability inherent within biological assays, but a clear
trend was apparent in the ranking of the VNAR variants.
14I1-M15 (IC50 15 mg/ml) was consistently the most po-
tent inhibitor, followed by 14M-8/14M-15/14I-1/14I1-Y2.
This provided further evidence that position 90 and 92
mutations are additive despite the kinetic data for AMA1
3D7 binding. No invasion inhibition was observed where af-
finities (as determined by Biacore) exceeded KD 600 nM
(Tables 1 and 2), suggesting that a threshold exists at
600 nM above which the antibody is unable to effectively
inhibit/compete for binding with the as yet uncharacter-
ized natural ligand for AMA1.
Structures of the VNAR-AMA1 Complex
We crystallized domains I and II of AMA1 3D7 (residues
N104–E438) (Gupta et al., 2005) in complex with both
VNARs 14I-1 and 14I1-M15. The crystallographic struc-
tures were refined to a similar R factor of 20% (resolution
2.35 and 2.45 A˚, respectively) and are almost identical for
both VNAR (root-mean-square deviation [rmsd] of 0.278/
0.350 A˚ for 114/116 residues) and AMA1 (rmsd of 0.379/
0.405 A˚ for 314/319 residues) molecules. Details of crys-
tallization and structure determination are provided in
Experimental Procedures, and statistics for X-ray data
collection and structure determination are summarized in
Table 3.
The overall structures reveal the VNAR CDR3 loop adopt-
ing an extended conformation and penetrating laterally
into an elongated hydrophobic cleft on the AMA1 surface
(Figure 3A). By targeting this cleft region, the VNAR6, November 2007 ª2007 Elsevier Ltd All rights reserved 1455
Table 1. VNAR Binding Kinet
VNAR Mutation
AMA1 HB3
Off-Rate:
Dissociation
Constant(1/s)
Binding
Affinity
KD(nm)
On-Rate:
Association
Constant(1/ms)
Off-Rate:
Dissociation
Constant(1/s)
12Y-2 None No bindinga No binding No binding No binding
14M-15 CDR3 Pro90Leu No binding No
bindinga
No bindinga No bindinga
14M-8 CDR1 Ala27Thr
CDR3 Phe100Leu
No bindinga No binding No binding No binding
14I-1 CDR1 Phe29Leu
CDR3 Gly92Arg
5.25 3 103 ±
2.75 3 104
717 ± 44 2.29 3 104 ±
1.14 3 102
1.64 3 102 ±
1.05 3 103
14I1-Y2 CDR3 Gly92Arg 8.13 3 103 ±
1.17 3 103
1808 ± 41 8.84 3 103 ±
2.57 3 103
1.60 3 102 ±
4.71 3 103
14I1-M15 CDR3 Pro90Leu
Gly92Arg
8.11 3 103 ±
6.55 3 104
832 ± 174 2.19 3 104 ±
1.97 3 103
1.81 3 104 ±
3.62 3 103
14I1-M8 CDR3 Gly92Arg
Phe100Leu
No binding No bindinga No bindinga No bindinga
12A-9 None No binding No binding No binding No binding
a Inconsistent/low-level binding
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AMA1 3D7 AMA1 W2mef
Binding
Affinity
KD(nm)
On-Rate:
Association
Constant(1/ms)
Off-Rate:
Dissociation
Constant(1/s)
Binding
Affinity
KD(nm)
On-Rate:
Association
Constant(1/ms)
708 ± 357 2.38 3 104 ±
1.22 3 104
1.32 3 102 ±
1.94 3 103
No
bindinga
No
bindinga
31 ± 6.8 8.80 3 104 ±
8.74 3 103
2.76 3 103 ±
7.33 3 104
No
binding
No
binding
31 ± 2.2 8.32 3 104 ±
4.03 3 103
2.57 3 103 ±
1.15 3 104
No bindinga No bindinga
4.8 ± 2.2 8.37 3 104 ±
1.05 3 104
4.12 3 104 ±
1.65 3 104
141 ± 13 3.73 3 104 ±
2.40 3 103
6.4 ± 1.6 1.15 3 105 ±
2.26 3 104
7.43 3 104 ±
1.56 3 104
690 ± 46 1.18 3 104 ±
2.45 3 103
4.7 ± 2.0 1.27 3 105 ±
5.23 3 104
6.37 3 104 ±
6.65 3 105
278 ± 8 2.91 3 104 ±
2.05 3 103
570 ± 226 9.47 3 103 ±
1.78 3 103
2.78 3 103 ±
2.12 3 104
No binding No binding
No binding No binding No binding No binding No binding
.
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Structure of an IgNAR-P. falciparum AMA1 ComplexFigure 2. Parasite Invasion Inhibition
(A) Recombinant VNAR domains inhibit invasion of erythrocytes by P. falciparum 3D7 parasites. Data are represented as the mean ± standard error of
quadruplicate experiments.
(B) As for (A) except for P. falciparum W2mef parasites.bypasses a large proportion of the highly variable poly-
morphic loop regions present on the previously described
surface-exposed face of the AMA1 molecule (Figures 3B
and 3C) (Bai et al., 2005). The molecular surface areas
buried by the VNAR-AMA1 complexes are extensive:
1205 A˚2 for 14I-1 and 1237 A˚2 for 14I1-M15. These figures
compared favorably with complexes observed in other
antibody-antigen interactions; however, many of these
studies used differing programs, probe radii, and input
parameters. Thus, in order to ensure consistency, we
recalculated buried surfaces using the same program and
probe parameters for a representative set of IgNAR and
VHH single-domain antibodies, and conventional anti-
bodies targeting either AMA1 or cleft-like structures (Table
S2). These figures confirmed our hypothesis that the VNAR-
AMA1 interface is one of the most extensive reported,
comparable with representative single-domain and con-Structure 15, 1452–146ventional antibodies derived from immunization of
experimental animals. For example, the VNARs PBLA8
(799 A˚2) and HEL-5A7 (897 A˚2), and VHHs cAbLys3 (908 A˚
2)
and AMD9 (1025 A˚2), were raised in sharks and camelids,
respectively, and target the active site clefts of either
lysozyme or a-amylase through extended CDR regions
(Table S2). Interestingly, the buried surface area for the
monoclonal inhibitory antibody 1F9, which also targets
P. falciparum 3D7 (Coley et al., 2007), similarly buries
an unusually large area on the AMA1 surface (1312 A˚2).
The epitopes for this conventional murine antibody and
the VNARs described here overlap to a considerable
degree (Figure 3D). The shape complementarity values
(Lawrence and Colman, 1993) of Sc = 0.71/0.66 for the
VNAR-AMA1 14I-1/14I1-14M15 complexes are also well
within the accepted range for antibody-protein antigen
interfaces.6, November 2007 ª2007 Elsevier Ltd All rights reserved 1457
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Structure of an IgNAR-P. falciparum AMA1 ComplexTable 2. Relative IC50 and IC30 Values for VNAR Inhibition of Parasite Erythrocyte Invasion
VNAR Mutation
AMA1 3D7 AMA1 W2mef
IC50 IC30 IC50 IC30
12Y-2 None — — — —
14M-15 CDR3 Pro90Leu 22 mg/ml 18 mg/ml — 120 mg/ml
14M-8 CDR1 Ala27Thr; CDR3 Phe100Leu 22 mg/ml 18 mg/ml — 90 mg/ml
14I-1 CDR1 Phe29Leu; CDR3 Gly92Arg 32 mg/ml 22 mg/ml 118 mg/ml 90 mg/ml
14I1-Y2 CDR3 Gly92Arg 40 mg/ml 28 mg/ml — 130 mg/ml
14I1-M15 CDR3 Pro90Leu; CDR3 Gly92Arg 14 mg/ml 10 mg/ml 70 mg/ml 52 mg/ml
14I1-M8 CDR3 Gly92Arg; CDR3 Phe100Leu 180 mg/ml 130 mg/ml — 180 mg/ml
12A-9 None Noninhibitory Noninhibitory Noninhibitory NoninhibitoryVNAR Conformational Changes upon
Antigen Binding
The 14I-1 and 14I1-M15 CDR3 and CDR1 region electron
densities were sufficiently well defined (Figures 4A and 4B,
and data not shown) to allow comparison with the uncom-
plexed 12Y-2 VNAR structure (Protein Data Bank [PDB] ID
Table 3. Data Collection, Structure Determination, and
Refinement Statistics
Crystal AMA1/14I-1 AMA1/14I1-M15
Diffraction Data
Beamline PF BL17A PF BL17A
Space group P31 P31
Unit cell
dimensions (A˚)
76.33, 140.39 76.48, 140.98
Resolution range (A˚) 66.08–2.35
(2.41–2.35)
66.23–2.45
(2.51–2.45)
Wavelength (A˚) 1.0000 0.96426
Unique reflections 34,389 28,622
Redundancy 5.4 (5.2) 5.0 (2.1)
Data completeness (%) 100 (100) 94 (65)
I/s(I) 14.4 (1.0) 14.4 (1.6)
Rmerge (%)
a 0.10 (0.75)a 0.13 (0.57)a
Refinement
Rwork (%)
b 20.1 (28.6) 18.9 (24.7)
Rfree (%)
c 28.4 (40.3) 28.2 (37.1)
Rms deviations
Bond length (A˚) 0.014 0.011
Bond angle () 1.584 1.340
Values in parentheses are for the highest shell.
a Rmerge = ShklSjjIj  < Ij >j/ShklSjjIjj, where hkl specifies
unique indices, j indicates equivalent observations of hkl,
and < Ij > is the mean value.
b R = ShkljjFoj  jFcjj/ShkljFoj, where jFoj and jFcj are the
observed and calculated structure factor amplitudes, respec-
tively.
c Represents approximately 10% of the data.1458 Structure 15, 1452–1466, November 2007 ª2007 Elsevier Lcode: 1VES). Significant differences were observed for the
three CDR3 loop regions (Figure 4C). The Gly92Arg muta-
tion resulted in a laterally extended loop conformation
in both complexed crystallographic forms. As the original
glycine residue at this position allows significant confor-
mational freedom, it is unlikely that these differences
result from enhanced loop flexibility; rather, we suggest
that the arginine side chain moves laterally upon binding
to AMA1. Addition of Pro90Leu may then allow slightly en-
hanced loop conformational freedom (Figure 4C, compare
red and blue traces) sufficient to provide superior cross-
strain AMA1 interactions. Most significant were the varia-
tions observed in the position of aromatic residues Tyr94
and Tyr96. In the uncomplexed form, these residues point
away from the backbone and against each other in an
aromatic (phenyl) stacking interaction. When complexed
with AMA1 in the AMA1/14I-1 structure, they now contact
a network of AMA1 residues (see below) and adopt a
perpendicular T stacking interaction (3.3 A˚) relative to
each other (Figure 4C). The distribution of electron density
(Figure 4B, and data not shown) for these residues in
the AMA1/14I1-M15 structure suggests that Tyr94 flips
between an outward-facing orientation directed away from
the antigen (as shown in Figure 4C) and alternatively occu-
pancy of a hydrophobic pocket in the AMA1 hydrophobic
cleft, similar to that observed for the AMA1/14I-1 struc-
ture. This is reflected in the B factors for residues Asp93-
Tyr94-Asn95 in the 14I1-M15 structure (62.9 compared to
54.9 for the rest of the molecule). Comparison of the over-
laid CDR1 loops for all three structures indicated minimal
backbone displacement upon antigen binding (rmsd 12Y-
2/14I-1: 1.493 A˚; 12Y-2/14I1-M15: 1.373 A˚), with only
slight variations in side-chain orientation, most particularly
at positions Phe/Leu29 and Lys32 (Figure 4D). The CDR2
in IgNAR antibodies is vestigial, and in this instance does
not contact the AMA1 antigen.
Although these results suggest a possible example of
‘‘induced fit’’ upon antigen binding, definitive evidence
supporting this hypothesis will, however, require future
determination of the uncomplexed forms of both 14I-1
and 14I1-M15. In the only other structural analysis
of free and complexed IgNAR antibodies (Stanfield
et al., 2007), marked conformational distortion was alsotd All rights reserved
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Structure of an IgNAR-P. falciparum AMA1 ComplexFigure 3. Structures of the AMA1-VNAR
Complexes
(A) Overlaid crystallographic complexes be-
tween VNAR domains 14I-1 and 14I1-M15
(ribbons) and domains I and II of 3D7 AMA1
(surface representation). The elongated VNAR
CDR3 at the top of the molecule aligns with
and penetrates the AMA1 surface-exposed
hydrophobic cleft (pink). Polymorphic residues
which contribute to malarial immune avoid-
ance are shaded purple and represent highly
variable epitope loops surrounding the con-
served hydrophobic cleft.
(B) Alternative view of the complex. The poly-
morphic AMA1 face is only partially targeted
by the VNAR domains.
(C) Alternative view of the complex. The non-
polymorphic AMA1 face (putatively occluded
on the parasite surface) is not targeted by the
VNAR domain.
(D) Comparison of AMA1 surface footprints for
VNAR 14I-1 (yellow) and murine antibody 1F9
Fab (PDB ID code: 2Q8A) (lime) domains. The
distance threshold is 8 A˚.observed for two tyrosine residues within the CDR3 loop
which reorient toward the center of the loop upon binding
to lysozyme. The CDR1 loop in this case also underwent
significant displacement upon antigen binding. We previ-
ously reported the effect of mutating residue 61 within this
system (Kopsidas et al., 2006), which produced a clear
enhancement in affinity. This residue is positioned at the
apex of heavy loop 4 at the top of the VNAR structure,
ideally positioned to contact antigen. Surprisingly, in our
structures, this residue does not interact with AMA1 and
is positioned behind Lys32 and Asp33 (Lys61 Nz–Asp33
O = 3.4 A˚). As VNAR residue Asp33 potentially interacts
with AMA1 Lys230 (3.5 A˚), there is a possible functional
role in supporting CDR1, although it is difficult to reconcile
such long-range effects with a significant increase in
affinity.Structure 15, 1452–146VNAR Targeting of AMA1 Epitopes
The 14I-1 and 14I1-M15 VNARs contact a total of 21 and 22
residues, respectively (probe radius 4 A˚), on the AMA1
molecule (Figure 5A; Table S3). Because of slight differ-
ences between the structures, potential hydrogen bond
and salt bridge interactions vary for the two VNARs; a sub-
set of these interactions is shown in Table 4. The majority
of contacts are within the VNAR CDR3 loops, with lesser
but significant contributions from the CDR1 regions and
residues Ala1-Trp2 at the N terminus of the VNAR A strand
(Figures 5B and 5C). The affinity-enhancing VNAR mutation
Arg92 identified in this study primarily contacts AMA1
residues Asn173, Gln174, and Pro185 in both structures
(Table 4; Figures 6A and 6B), with additional contacts to
Thr186 and Glu187 either below (14I-1) or above (14I1-
M15) a 4 A˚ cutoff.6, November 2007 ª2007 Elsevier Ltd All rights reserved 1459
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Structure of an IgNAR-P. falciparum AMA1 ComplexFigure 4. CDR Conformations upon AMA1 Binding
(A) Electron density 2Fo Fc for the 14I-1 CDR3 loop (residues 86–102).
The map is contoured at 1.0s.1460 Structure 15, 1452–1466, November 2007 ª2007 ElsevierThe AMA1 hydrophobic cleft is formed by residues
Val169, Leu176, Phe183, Met190, Tyr202, Val208,
Met224, Tyr251, Ile252, Met273, Leu357, and Phe367.
The VNAR residues Tyr94 and Tyr96 potentially contact
Tyr251 through aromatic ring interactions (5.3 A˚) (Fig-
ure 6C; Table 4). This is a potentially important contact
due to the extremely high conservation of Tyr251 in AMA1s
across apicomplexan parasite species (Hehl et al., 2000).
The structure of the 14I1-M15 loop appears slightly more
flexible around Tyr96, allowing <4 A˚ contact with residue
Asn228 compared to 14I-1 (>5.5 A˚). An additional contact
(5.3 A˚) is present for 14I-1 through Asn371 and an asso-
ciated water molecule (Figure 6C; Table 4). VNAR residues
Leu89 and Phe100 make close contact with the con-
served hydrophobic cleft residues Met190, Tyr202, and
Met224 (Figure 6D, shown in orange; Table 4) as part of
a generalized series of salt bridge, hydrophobic, and aro-
matic interactions across the base and sides of the cleft.
This additionally includes VNAR residues Phe29/Leu29
inserting into a pocket formed by AMA1 residues Met190,
Met193, Pro188, Phe201, and Tyr202. At the C terminus
of the VNAR CDR3 loop, residue Arg101 (range of contacts
2.7–3.4 A˚) also makes significant charge and salt bridge
contributions to binding, and there are additional possible
contacts with residue Glu103 (Table 4).
To correlate levels of binding affinity and parasite inhibi-
tion with these structural data, we next mapped VNAR res-
idues that interact (<4 A
´
) with known AMA1 polymorphic
residues (Figure 5A; Table S3). Significant polymorphisms
(3D7-residue-W2mef/HB3) occur at positions Glu187Lys/
Glu, Met190Met/Ile, Phe201Leu/Leu, and Ile225Asn/Asn.
Most significant appear to be (1) Glu187Lys, where the
change from negative to positive charge may affect the
interaction with Arg92 on the CDR3 loop (Figure 6A); (2)
Phe201Leu, where hydrophobic interactions within an ar-
omatic pocket formed by VNAR residues Phe29, Tyr87, and
Phe100 of CDR3 and AMA1 residues Phe201 and Tyr202
may be disrupted (Figure 6D, cyan side chain); and (3)
Ile225Asn, where mutation in W2mef and HB3 results in
a change from hydrophobic to charged residue and may
prejudice interactions with VNAR Leu99 (3.0–3.8 A˚) (Table
4). For HB3, in addition to the above residue changes,
mutation Met190Ile (not present in W2mef) may affect the
interaction with a hydrophobic pocket formed by VNAR
residues Leu89 and Phe100 (Figure 6D). Notwithstanding
this dissection of interstrain differences, it should be noted
that significantly more polymorphic variations than listed
occur between these strains (Figure 5A). Although these
are structurally removed by more than 4 A˚ from the VNAR
paratope, they are almost certain to exert long-range
influence either by perturbing the conformation of the
(B) Electron density 2Fo  Fc for the 14I1-M15 CDR3 loop (residues 86–
102). The map is contoured at 1.0s. Note the low level of visible density
surrounding residues Tyr94 and Tyr96 at this contour.
(C) Superimposed representations of CDR3 backbone traces for VNARs
12Y-2 (yellow), 14I-1 (red), and 14I1-M15 (blue). Side chains are shown
for residues Pro/Leu90, Arg92, Tyr94, and Tyr96.
(D) Superimposed representations of CDR1 backbone and side-chain
traces for VNARs 12Y-2 (yellow), 14I-1 (red), and 14I1-M15 (blue).Ltd All rights reserved
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Structure of an IgNAR-P. falciparum AMA1 Complexhydrophobic cleft or by sterically altering orientation and
access to the epitope by the antibody, sufficient to alter
levels of binding affinity and parasite invasion inhibition
within the observed one to two orders of magnitude.
DISCUSSION
By employing the protein-engineering techniques of
targeted mutagenesis and library selection, we have
expanded the binding tropism of a low-affinity shark IgNAR
single-domain antibody fragment to AMA1 from three
Plasmodium strains, and enhanced binding affinity by an
order of magnitude. Even slight changes in CDR loop
topology can lead to significant variations in antibody affin-
ity, and the structures presented here illustrate this in the
context of epitope binding by an unusually long CDR3
loop. Acquisition of just one dominant mutation (Gly92Arg)
located at the apex of the CDR3 loop within the VNAR para-
tope produced significant enhancement in potency, and
we ascribe this effect to generation of a new series of hy-
drogen bond and salt bridge interactions with conserved
AMA1 residues. However, the additive effects of other mu-
tations also appeared necessary for enhanced biological
potency, for example the Pro90Leu mutation resulting
in potentially greater loop conformational freedom. Ulti-
mately, because of the broad range of potential contacts
within the 3–5 A˚ range encompassing an extensive net-
work of VNAR-AMA1 interactions, we are reluctant to defin-
itively ascribe the differences between 14I-1 and 14I1-M15
to any single set of contacts.
The Kinetics versus Biological Activity Question
for Antibody-Antigen Interactions
Of long-standing interest has been the mechanism by
which protective antibodies directed against AMA1 inhibit
red blood cell invasion, and how binding kinetics correlate
with in vivo activity (Saul, 1987). Our data shed significant
light on these issues by allowing us to compare the effect
of defined mutations on both kinetic biosensor affinities
and erythrocyte invasion inhibition. Within the constraints
of comparing in vitro protein chemistry with a biological
assay, it is interesting that the variants 14I-1 and 14I1-M15
both plateau at an affinity of 5 nM, whereas 14I1-M15
was consistently more inhibitory of invasion. We suggest
that the results from immobilization to a solid surface (Bia-
core) constrain AMA1 flexibility, compared to the greater
inherent fluidity associated with presentation on the para-
site surface. Additionally, the 14I1-M15 CDR loop appears
more flexible in the crystallographic structures than its
14I-1 counterpart (as evidenced by electron density pat-
terns), suggesting that increased conformational freedom
leads to a superior fit upon antigen binding.
The measurable affinities of the antibody variants de-
scribed here vary over an almost 400-fold range (above
which binding is not detected), and the differences appear
to be through prolonged dissociation phases (off-rates)
rather than enhanced association (on-rates) for the com-
plexes. Because of the overlapping standard errors for
the results from multiple biosensor experiments, we areStructure 15, 1452–146unable to conclusively answer the question of whether
association rate is the true mediator of parasite invasion
efficiency (Saul, 1987); however, our results strongly sup-
port a model where differences in the dissociation rate
kinetics are at least equally as important in competition for
the AMA1 ligand.
The Immune System: Parasite Arms Race and
Implications for Anti-Malarial Drugs
Mechanistically, the multiple polymorphic loops surround-
ing the conserved hydrophobic cleft which bisects the
AMA1 surface are ideally placed to foil molecules of the
conventional vertebrate immune repertoire through a com-
bination of steric hindrance and epitope variation. Thus,
immunization of humans with AMA1 is unlikely to induce
an antibody response that effectively targets the underly-
ing conserved epitopes, as it requires a rare selection
event in the host, as for the b12 anti-HIV gp120 antibody
(Zhou et al., 2007), to produce this type of antibody para-
tope. However, our data, when combined with previous
AMA1 structural studies, now illustrate the possibility of
specific classes of single-domain reagents capable of
penetrating and occupying the AMA1 cleft region. The
success of camelid VHH antibodies in targeting otherwise
cryptic epitopes on variable surface glycoproteins of Afri-
can trypanosomes (Stijlemans et al., 2004) is a similar and
compelling example of parasite immune avoidance and
counterstrategy by the vertebrate immune system, and sug-
gests that such single-domain antibody structures may be
particularly good at targeting parasite surfaces and similar
antigenic sites that are refractory to antibody recognition
(Colman et al., 1987).
Our future work will concentrate on structure-based
mutagenesis and design of this family of VNAR antibodies,
aiming to target the more conserved AMA1 hydrophobic
cleft residues and derive binding proteins capable of
breaching the species barrier between P. falciparum and
P. vivax. By extension to a murine model of malaria, we
will be able to more fully correlate laboratory-based
assays with efficacy in a living system. By understanding
the mechanistic processes by which binding agents target
this important malarial protein, we aim to guide our design
of small-molecule drugs targeting this conserved region
of AMA1 and thereby minimize the risk of evasion by the
parasite, as well as advancing our understanding of the
advantages offered by different forms of antibody archi-
tectures. Further, an understanding of the importance of
individual AMA1 residues and the conformation they as-
sume upon antibody binding will be equally applicable to
the design of enhanced anti-AMA1 vaccines, where the
influence of the polymorphic residues is ameliorated,
while retaining the essence of the underlying neutralizing
epitope.
EXPERIMENTAL PROCEDURES
Cloning and Construction of VNAR Phage Display Library
Cell lines used for library propagation and protein expression were
E. coli TG1 and E. cloni 10GF0 (Lucigen, Middleton, WI, USA). The6, November 2007 ª2007 Elsevier Ltd All rights reserved 1461
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Structure of an IgNAR-P. falciparum AMA1 ComplexTable 4. Representative VNAR-AMA1 Contacts
VNAR AMA1/14I-1 Distance (A˚) VNAR AMA1/14I1-M15 Distance (A˚)
Leu89 CG–Thr186 CG2 3.8 Leu89 CA–Glu187 O 3.3
Leu89 CD1–Met190 CG 3.9 Leu89 CD2–Met190 CG 3.8
Arg92 NH2–Asn173 O 4.0 Arg92 NH1–Asn173 OD1 3.7
Arg92 NH2–Gln174 CG 3.3 Arg92 NH1–Glu174 CG 3.2
Arg92 N–Pro185 O 3.0 Arg92 N–Pro185 O 3.3
Arg92 N–Thr186 CA 3.9
Arg92 CB–Glu187 CG 3.6
Tyr94 OH–Thr171 O 3.6
Tyr96 OH–Tyr251 OH 5.3 Tyr96 OH–Asn228 N 3.9
Leu98 CD2–Thr186 CD2 3.8
Leu99 CB–Ile225 CB 3.5 Leu99 CB–Ile225 CB 3.8
Leu99 O–Ile225 N 3.0 Leu99 O–Ile225 N 3.4
Phe100 CA–Asn233 O 3.4 Phe100 CA–Asn233 O 3.6
Phe100 CD1–Met224 CE 3.3 Phe100 CD1–Met190 CG 3.7
Phe100 CZ–Phe201 CE2 3.5 Phe100 CZ–Asn233 CB 3.5
Phe100 CZ–Tyr202 OH 3.6 Phe100 CZ–Tyr202 OH 3.8
Arg101 N–Asn233 O 2.7 Arg101 N–Asn233 O 2.3
Arg101 NE–Gly222 O 2.9 Arg101 CZ–Ile225 CD1 4.0
Arg101 NH1–Gly222 O 3.4 Arg101 NH1–Lys230 O 3.1
Arg101 NH2–Ile225 CD1 3.0 Arg101 NH2–Ile225 CD1 3.0
Glu103 OE2–Asn205 ND2 3.0 Glu103 OE2–Asn205 ND2 2.4
Glu103 OE1–Asp204 O 3.9 Glu103 OE2–Asn205 CG 3.4VNAR library was constructed by splice-overlap PCR as previously
described (Nuttall et al., 2003) using VNAR 12Y-2-derived DNA templates
(Nuttall et al., 2004). Loop randomization used six degenerate oligonu-
cleotide primers (KH0001, KH0002, KH0003, KH0004, KH0005,
KH0006; Table S1) and the 50 primer 8408. Restriction endonuclease
sites were added using oligonucleotide primer combination 8408 and
8404 (Table S1). Library cloning was as previously described (Nuttall
et al., 2001) yielding a final library size of >5 3 107 clones. DNA
sequencing (ABI Prism BigDye terminator cycle sequencing kit, v.
3.1, Applied Biosystems, Foster City, CA, USA; Australian Genome
Research Facility, Melbourne) verified equal representation of random-
ization strategies in the final library.
AMA1 Protein Production
Variant recombinant P. falciparum AMA1 proteins from strains 3D7,
W2mef, and HB3 were produced as described (Gupta et al., 2005;
Hodder et al., 2001). In brief, proteins were expressed in E. coli with
an N-terminal His tag, solubilized, purified using several nickel-NTA-
affinity chromatography steps, and refolded in a buffer containing a
redox couple. Proteins were further purified using anion-exchangeStructure 15, 1452–146chromatography, size-exclusion chromatography, and reverse-phase
HPLC.
Selection of AMA1-Binding VNARs
Phagemid particles displaying the VNAR-g3p fusion library were pro-
duced and biopanned (Nuttall et al., 2003) against AMA1 antigens
(0.25–2.5 mg/ml) coated onto Maxisorb immunotubes (Nunc-Nalge
International, Roskilde, Denmark). The wash regime was: round 1: 15
washes with PBS, 0.1% Tween 20; 15 washes with PBS; rounds 2,
3, and 4: 20 washes with PBS, 0.1% Tween 20; 20 washes with PBS.
Post-fourth-round selection, eluted phages were infected into TG1
cells and propagated as plasmids (Nuttall et al., 2004).
Construction and Expression of VNAR Variants
Seven VNAR variants (Figure 1E) were constructed by sequential PCR
using oligonucleotides 8408 (50) and A1703, A1704, A1705, and 8404
(30) (Table S1) in combination with VNAR 12Y-2, 14M-8, and 14M-15
DNA templates (Nuttall et al., 2004). DNA cassettes were cloned as
above and verified by bidirectional DNA sequencing. Recombinant
VNAR proteins were expressed into the E. coli periplasmic spaceFigure 5. VNAR-AMA1 Contacts
(A) Alignment of AMA1s from P. falciparum strains 3D7, W2mef, and HB3 (residues N104–E438). Residues polymorphic between strains are boxed.
Conserved hydrophobic cleft residues are underlined and asterisked. Residues in contact with VNARs 14I-1 and 14I1-M15 (magenta), 14I-1 only (red),
or 14I1-M15 only (blue) are indicated.
(B) Stereo images of the 14I-1 backbone (red) penetrating the AMA1 hydrophobic cleft (gray). Side chains of AMA1 residues within 4 A˚ of the VNAR
backbone are shown, including hydrophobic residues forming the base of the hydrophobic cleft (orange) and residues polymorphic between
P. falciparum strains 3D7, W2mef, and HB3 (cyan).
(C) As for (B) except for 14I1-M15 backbone (blue).6, November 2007 ª2007 Elsevier Ltd All rights reserved 1463
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(A) VNAR residue Arg92 contacts AMA1 resi-
dues Asn173, Glu174, Pro185, Thr186, and
Glu187 (<4 A˚) in a series of hydrogen bond
and salt bridge interactions in the 14I-1 crystal-
lographic structure. Residue coloring is as for
Figure 5.
(B) As for (A) except for the VNAR 14I1-M15
structure.
(C) VNAR residues Tyr94, Tyr96, and Leu98 in
the 14I-1 structure contact hydrophobic cleft
residues Phe183 and Tyr251, and associated
residue Asn371, through a network of water-
mediated hydrogen bonds and potential aro-
matic interactions.
(D) VNAR residues Leu89 and Phe100 in the 14I-1
structure are closely associated with AMA1
residues within the hydropobic cleft (Met190,
Tyr202, Met224) and residues polymorphic be-
tween P. falciparum strains (Met190, Phe201).(Nuttall et al., 2001) and assayed in crude form, or purified by affinity
chromatography through an anti-FLAG Ig/Sepharose column (10 3 1
cm) equilibrated in Tris-buffered saline. Proteins were analyzed by
SDS-PAGE, western blotting, and size-exclusion chromatography
(FPLC) on a precalibrated Superdex 75 column (Amersham Pharmacia
Biotech, Uppsala, Sweden) in PBS (analytical) or 10 mM HEPES (pH
7.4), 150 mM NaCl, 0.05% Tween 20 (biosensor analysis). ELISA anal-
ysis was as described (Nuttall et al., 2004).
Determination of Binding Affinity by Surface Plasmon
Resonance
A Biacore T100 biosensor (Papalia et al., 2006) was used to measure
kinetic binding interactions between recombinant VNAR and AMA1
proteins. All immobilizations were performed at 25C with HBS-EP+
buffer (10 mM HEPES [pH 7.4], 150 mM NaCl, 3.4 mM EDTA, 0.05%
surfactant P20) as running buffer. AMA1 proteins were immobilized
on CM5 sensor chips using standard amine-coupling chemistry: the
carboxymethyl dextran surface was activated with 1:1 0.4 M 1-ethy-
3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC):0.1 M
N-hydroxysuccinimide (NHS). ‘‘Aim-for-immobilized-level’’ wizard
template (Biacore T100 control software; v. 1.1.1) was utilized for cou-
pling of AMA1 proteins to the surface, whereby small volumes (1–9 ml)
of AMA1 proteins (12.5 mg/ml, 10 mM sodium acetate [pH 4.5]) were
automatically injected (5 ml/min) over the activated surface until immo-
bilization of 1000 RU was achieved. The immobilization procedure
was completed by 1 M ethanolamine (pH 8.5) (7 min injection/10 ml/
min) to deactivate residual reactive sites. All binding experiments
were performed in HBS-EP+ buffer at a constant flow rate (30 ml/min)
with a series of analyte (VNAR) concentrations. Regeneration of the
AMA1 protein surface was achieved with a single 30 s injection of
10 mM glycine solution (pH 1.5). Binding data were evaluated using
Scrubber software v.2.1 (http://www.biologic.com.au).1464 Structure 15, 1452–1466, November 2007 ª2007 ElsevierParasite Culture and Invasion Inhibition Assays
P. falciparum strains were cultured as previously described (Lambros
and Vanderberg, 1979) and synchronized using the sorbitol method
(Trager and Jensen, 1976). Invasion inhibition assays were performed
as described (Basco et al., 1995; Kennedy et al., 2002). Further details
are available in the Supplemental Data.
Crystallization
Recombinant P. falciparum AMA1 domains I and II (Gupta et al., 2005)
and VNARs 14I-1 or 14I1-M15 were mixed in 1:1 stoichiometric ratios
and set up as 0.2 ml hanging drops (Cartesian honey bee 16 Robot; Ge-
nomic Solutions, Ann Arbor, MI, USA). Plates were incubated at 25C.
Successful conditions were scaled to 2 ml hanging drops. Final crystal-
lization conditions for AMA1 DI and II and VNAR 14I1-M15 were 0.1 M
phosphate citrate (pH 4.2), 0.2 M NaCl, 20% polyethylene glycol
(PEG) 8000. Diffraction-quality crystals (space group P31) were ob-
tained after 48 hr. Final crystallization conditions for AMA1 DI and II
and VNAR 14I-1 were 0.1 M phosphate citrate (pH 4.2), 0.2 M NaCl,
15% PEG 8000. Diffraction-quality crystals (space group P31) were
obtained after 48 hr.
Data Collection and Structure Determination
X-ray diffraction data were collected at the Photon Factory (Tsukuba,
Japan). Data were collected at 160C and processed using the
HKL2000 suite (Otwinowski and Minor, 1997). Diffraction data statis-
tics are summarized in Table 3. Location of the AMA1 and VNAR do-
mains was by molecular replacement using PHASER (McCoy et al.,
2005). Search models were AMA1 (Bai et al., 2005) and VNAR 12Y-1
(Streltsov et al., 2004). Phase improvement used BUSTER-TNT (Blanc
et al., 2004) with the resultant electron density map used to build miss-
ing fragments. Model building and crystallographic refinement used it-
erative cycles of BUSTER-TNT and/or REFMAC5 (Murshudov et al.,
1997) and manual model building using XtalView/Xfit (McRee, 1999).Ltd All rights reserved
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Structure of an IgNAR-P. falciparum AMA1 ComplexWithin BUSTER-TNT, scattering from missing atoms was modeled
with a low-resolution homographic exponential distribution, and max-
imum entropy density completion was employed following each round
of refinement to recover density for missing parts of the structure.
Water molecules were added and revised with XtalView. Progress of
the refinement was monitored using the Rfree statistic based on a set
encompassing 10% of the observed diffraction amplitudes. Following
the convergence in standard REFMAC5 refinement, further improve-
ment of R factors was achieved by refining all chains as separate rigid
anisotropic domains with the translation, libration, and screw-rotation
displacement procedure. The libration tensor showed significant an-
isotropy. The final refinement converged to R/Rfree values of 0.201/
0.284 and 0.189/0.282 for AMA1/14I-1 and AMA1/14I1-M15, respec-
tively. Further details are given in the Supplemental Data.
Supplemental Data
The Supplemental Data include two figures, three tables, and Supple-
mental Experimental Procedures and can be found with this article on-
line at http://www.structure.org/cgi/content/full/15/11/1452/DC1/.
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